<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The rapid degradation and subsequent lack of efficacy of <z:chebi fb="0" ids="30772">n-butyric acid</z:chebi> in vivo has been improved by the synthesis of <z:chebi fb="1" ids="35381">monosaccharide</z:chebi> stable pro-drugs of <z:chebi fb="4" ids="30772">butyric acid</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the effects of D1 (O-n-<z:chebi fb="0" ids="22972">butanoyl</z:chebi>-2,3-O-<z:chebi fb="0" ids="29858">isopropylidene</z:chebi>-alpha-D-mannofuranoside), G1 (1-O-n-<z:chebi fb="0" ids="22972">butanoyl</z:chebi>-D,L-<z:chebi fb="0" ids="17151">xylitol</z:chebi>), and F1 (1-O-n-<z:chebi fb="0" ids="22972">butanoyl</z:chebi> 2,3-O-<z:chebi fb="0" ids="29858">isopropylidene</z:chebi>-D,L-<z:chebi fb="0" ids="17151">xylitol</z:chebi>) on the maturation and proliferation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> 60 and FLG 29.1 and of purified blast cells from 10 cases of de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell maturation was measured by surface antigen expression, <z:mp ids='MP_0000002'>morphology</z:mp> and cytochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>Toxicology in mice was also evaluated (DL50 1000 mg/kg) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> 60 cells G1 and D1 increased the expression of CD15 and CD11a (presenting 62% of promyelo-metamyelocytes), and in 7/10 cases of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> that of CD11a, CD11b, CD15, and myeloperoxidase </plain></SENT>
<SENT sid="5" pm="."><plain>D1, G1 and F1 induced a dose-dependent inhibition of <z:chebi fb="0" ids="53526">tritiated thymidine</z:chebi> uptake </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> (evaluated by flow cytometry and <z:chebi fb="2" ids="2511">agarose</z:chebi> gel electrophoresis) was induced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts by D1 and F1 (79% and 94% respectively for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> 60 cells) and, with less effect, by G1 (27%) </plain></SENT>
<SENT sid="7" pm="."><plain>The persistence of maturative and apoptotic activity in these new pro-drugs of <z:chebi fb="4" ids="30772">butyric acid</z:chebi>, hydrolysed only inside the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell, suggests a possible use in differentiation therapy of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> </plain></SENT>
</text></document>